Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H25NO2.ClH |
Molecular Weight | 347.879 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(CN1CCOCC1)CC2=CC=C(COC3=CC=CC=C3)C=C2
InChI
InChIKey=HWDXMCUKRADNLV-UHFFFAOYSA-N
InChI=1S/C20H25NO2.ClH/c1-2-6-20(7-3-1)23-17-19-10-8-18(9-11-19)5-4-12-21-13-15-22-16-14-21;/h1-3,6-11H,4-5,12-17H2;1H
Molecular Formula | C20H25NO2 |
Molecular Weight | 311.418 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1687682 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8786420 |
100.0 µM [Ki] | ||
Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20727863 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Erbocain Approved UseUnknown Launch Date1966 |
PubMed
Title | Date | PubMed |
---|---|---|
Local anaesthetic effectivity and toxicity of fomocaine, five N-free fomocaine metabolites and two chiralic fomocaine derivatives in rats compared with procaine. | 2001 |
|
[Synthesis and pharmacologic action of chiral fomocaine ((4-[2-methyl-3-(morpholin-4-yl)propyl)benzyl)-phenyl-ether and (4-(1-methyl-3-(morpholin-4-yl)propyl]benzyl)-phenyl-ether). 13. Synthesis of new compounds with local anesthetic action]. | 2001 Aug |
|
[[Physical chemical, pharmacological and toxicologic properties of fomocaine metabolites] ]. | 2001 Jan |
|
Local anaesthetic effects and toxicity of seven new diethanolamine and morpholine derivatives of fomocaine. Testing in rats compared with procaine and tetracaine. | 2003 |
|
In vitro interactions with the Cytochrome P450 system, toxicity, and local anaesthetic effects of Fomocaine Alkylmorpholine derivatives in rats. | 2006 |
|
[In vitro investigations of phase I metabolism of the fomocaine derivative Oe 9000 with pig liver homogenates]. | 2006 Nov |
|
A synopsis on different homologous series of fomocaine derivatives. In vitro interactions with the cytochrome P450 system, toxicity, and local anaesthetic effects in rats--Part III. | 2007 |
|
A synopsis on different homologous series of fomocaine derivatives. In vitro interactions with the cytochrome P450 system, toxicity, and local anaesthetic effects in rats--part II. | 2007 |
|
Blockade of TTX-resistant and TTX-sensitive Na+ currents in cultured dorsal root ganglion neurons by fomocaine and the fomocaine derivative Oe 9000. | 2010 Oct 28 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2619777
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:33:36 GMT 2023
by
admin
on
Sat Dec 16 08:33:36 GMT 2023
|
Record UNII |
96285SEX30
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
171527
Created by
admin on Sat Dec 16 08:33:36 GMT 2023 , Edited by admin on Sat Dec 16 08:33:36 GMT 2023
|
PRIMARY | |||
|
DTXSID80205137
Created by
admin on Sat Dec 16 08:33:36 GMT 2023 , Edited by admin on Sat Dec 16 08:33:36 GMT 2023
|
PRIMARY | |||
|
56583-43-8
Created by
admin on Sat Dec 16 08:33:36 GMT 2023 , Edited by admin on Sat Dec 16 08:33:36 GMT 2023
|
PRIMARY | |||
|
96285SEX30
Created by
admin on Sat Dec 16 08:33:36 GMT 2023 , Edited by admin on Sat Dec 16 08:33:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |